



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Chunli Zheng
✉ chunlizheng@126.com
Jinglin Zhu
✉ zhujinglin27@163.com
Yahui Jin
✉ sxxajyh@126.com

RECEIVED 18 October 2025
ACCEPTED 30 October 2025
PUBLISHED 07 November 2025

CITATION

Zhang Y, Guan H, Feng X, Liu M, Shao J, Liu M, He J, Jin Y, Zhu J and Zheng C (2025) Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival. *Front. Immunol.* 16:1727580. doi: 10.3389/fimmu.2025.1727580

COPYRIGHT

© 2025 Zhang, Guan, Feng, Liu, Shao, Liu, He, Jin, Zhu and Zheng. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

Yu Zhang, Haixia Guan, Xixuan Feng, Mengyan Liu, Jinhuan Shao, Mengchi Liu, Jialei He, Yahui Jin*, Jinglin Zhu* and Chunli Zheng*

Yan'an Medical College, Yan'an University, Yan'an, Shaanxi, China

KEYWORDS

colorectal cancer immunotherapy, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, matrix-depletion therapy

A Correction on

Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

By Zhang Y, Guan H, Feng X, Liu M, Shao J, Liu M, He J, Jin Y, Zhu J and Zheng C (2025) *Front. Immunol.* 16:1616414. doi: 10.3389/fimmu.2025.1616414

There was a mistake in **Table 7** as published. The phases corresponding to NCT06751966 and NCT06751914 were omitted. The corrected **Table 7** appears below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 7 Clinical trials based on neoantigen vaccines for the treatment of colorectal cancer.

ClinicalTrials.Gov identifier	Combinatorial agent(s)	Phase	Primary endpoint	Status
NCT03948763	Pembrolizumab	Phase 1	DLTs	Terminated
NCT06195384		Phase 1	Safety	Recruiting
NCT06496373		Phase 1	Reaction of antigen-specific T cells	Recruiting
NCT05359354		Not Applicable	MTD,DLTs	Recruiting
NCT05916248	Pembrolizumab	Phase 1	MTD,DLTs,ORR,DCR	Recruiting
NCT05940181	Sintilimab	Interventional	MTD,DLTs,Safety	Recruiting
NCT06497010		Phase 1	RP2D	Recruiting
NCT03639714	Nivolumab;Ipilimumab	Phase 1,2	TEAEs,DLTs,ORR, RP2D	Completed
NCT06751966		Not Applicable	ORR,DCR,Safety	Recruiting
NCT06751914		Not Applicable	ORR,DCR,Safety	Recruiting
NCT04147078		Phase 1	DFS	Recruiting
NCT04117087	Nivolumab;Ipilimumab	Phase 1	Safety,Fold change in CD8 and CD4 T cells	Recruiting
NCT02600949		Phase 1	Feasibility,TEAEs	Recruiting
NCT03552718		Phase 1	Safety,RP2D	Active
NCT04041310	Pembrolizumab	Phase 1,2	DLTs,ORR,Safety, Tolerability	Active
NCT03953235	Nivolumab;Ipilimumab	Phase 1,2	TEAEs,DLTs, ORR, RP2D	Completed
NCT04912765	Nivolumab	Phase 2	PFS	Recruiting
NCT06522919	Pembrolizumab	Phase 2	ORR,PFS	Recruiting
NCT05141721	Atezolizumab;Fluoropyrimidine;Bevacizumab; Ipilimumab	Phase 2,3	ctDNA,PFS	Active